Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15796463 | 1.00 | NAAA (0.52) | NAAAEPHX1TSHRSPHK1HCAR2 | |
| SCHEMBL27733410 | 1.00 | NAAA (0.52) | NAAAEPHX1TSHRSPHK1HCAR2 | |
| SCHEMBL462188 | 1.00 | NAAA (0.52) | NAAAEPHX1TSHRSPHK1HCAR2 | |
| SCHEMBL138880 | 1.00 | NAAA (0.52) | NAAAEPHX1TSHRSPHK1HCAR2 | |
| SCHEMBL15305328 | 1.00 | NAAA (0.52) | NAAAEPHX1TSHRSPHK1HCAR2 | |
| SCHEMBL21184186 | 1.00 | NAAA (0.52) | NAAAEPHX1TSHRSPHK1HCAR2 | |
| SCHEMBL15796319 | 1.00 | NAAA (0.52) | NAAAEPHX1TSHRSPHK1HCAR2 | |
| SCHEMBL15305326 | 1.00 | NAAA (0.52) | NAAAEPHX1TSHRSPHK1HCAR2 | |
| SCHEMBL15796587 | 1.00 | NAAA (0.52) | NAAAEPHX1TSHRSPHK1HCAR2 | |
| Hydrochloric Acid SCHEMBL15568552 | 0.98 | NAAA (0.50) | NAAAEPHX1TSHRSPHK1HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113274-A1 | Hydrocarbyl aminohydrocarbonoates and aminohydrocarbonol hydrocarbonoates as antimicrobial and antiviral agents | MIDWEST RESEARCH LABORATORIES, LLC | 2005-05-26 | — | — | US | claimed |
| EP-2613772-B1 | LOW-DOSE TRANSDERMAL PATCHES WITH HIGH DRUG RELEASE | BAYER IP GMBH (DE) | 2016-12-14 | — | — | EP | disclosed |
| US-9005653-B2 | Transdermal delivery of hormones with low concentration of penetration enhancers | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-20150079163-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE | NEXMED HOLDINGS, INC. | 2015-03-19 | — | — | US | disclosed |
| US-20140357713-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE | NEXMED HOLDINGS, INC. (US) | 2014-12-04 | — | — | US | disclosed |
| US-20140357713-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE | NEXMED HOLDINGS, INC. (US) | 2014-12-04 | — | — | US | disclosed |
| US-8900625-B2 | Antimicrobial compounds and methods of use | NEXMED HOLDINGS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140170207-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE | NEXMED HOLDINGS, INC. | 2014-06-19 | — | — | US | disclosed |
| US-20140109916-A1 | Transdermal Delivery of Hormones without the Need of Penetration Enhancers | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-24 | — | — | US | disclosed |
| US-8671945-B2 | Low-dose transdermal patches with high drug release | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| EP-2138169-B1 | Transdermal delivery system of hormones without penetration enhancers | BAYER IP GMBH (DE) | 2013-11-06 | — | — | EP | disclosed |
| EP-2613772-A2 | LOW-DOSE TRANSDERMAL PATCHES WITH HIGH DRUG RELEASE | Bayer Intellectual Property GmbH (DE) | 2013-07-17 | — | — | EP | disclosed |
| US-20120073578-A1 | LOW-DOSE TRANSDERMAL PATCHES WITH HIGH DRUG RELEASE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-29 | — | — | US | disclosed |
| WO-2012031999-A2 | LOW-DOSE TRANSDERMAL PATCHES WITH HIGH DRUG RELEASE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-15 | — | — | WO | disclosed |
| EP-2138169-A2 | Transdermal delivery system of hormones without penetration enhancers | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-12-30 | — | — | EP | disclosed |
| WO-2005058287-A2 | TRANSDERMAL DELIVERY SYSTEM OF HORMONES WITHOUT PENETRATION ENHANCERS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-06-30 | — | — | WO | disclosed |
| US-20050142175-A1 | Transdermal delivery of hormones without the need of penetration enhancers | LUYE PHARMA SWITZERLAND AG (CH) | 2005-06-30 | — | — | US | disclosed |
| EP-1541137-A2 | Transdermal delivery system of hormones without penetration enhancers | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005051960-A2 | HYDROCARBYL AMINOHYDROCARBONOATES AND AMINOHYDROCARBONOL HYDROCARBONOATES AS ANTIMICROBIAL AND ANTIVIRAL AGENTS | MIDWEST RESEARCH LABORATORIES, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20050113274-A1 | Hydrocarbyl aminohydrocarbonoates and aminohydrocarbonol hydrocarbonoates as antimicrobial and antiviral agents | MIDWEST RESEARCH LABORATORIES, LLC | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150079163-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE | CLPP, POLR1C, NACA | NAAA 189/4885EPHX1 3515/4885TSHR 4806/4885 |
| US-20140170207-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE | CLPP, POLR1C, NACA | NAAA 189/4885EPHX1 3515/4885TSHR 4806/4885 |
| US-20140357713-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE | CLPP, POLR1C, NACA | NAAA 189/4885EPHX1 3515/4885TSHR 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.